Beam Therapeutics Inc. is an American biotechnology company based in Cambridge, Massachusetts. It develops genetic medicines using base editing, or base editing. This technology aims to convert one DNA letter into another in a targeted manner, without cutting both strands of the molecule. The goal is to correct certain mutations or modify the expression of genes involved in a disease.
A company rooted in CRISPR research
Founded in 2017, Beam Therapeutics builds on the work of researchers including David Liu, Feng Zhang and J. Keith Joung. Its history is part of the evolution of CRISPR tools, which have opened up new possibilities for targeted genome manipulation. Base editing combines a DNA recognition system with enzymatic activity capable of chemically transforming some of its components.
Listed on Nasdaq in 2020 under the ticker symbol BEAM, the company seeks to turn this scientific platform into treatments. It operates as an integrated biotech company: selecting targets, designing editors, conducting preclinical and clinical development, and then preparing for manufacturing. It must therefore reconcile molecular innovation, regulatory requirements and industrial constraints.
Two routes to reach diseased cells
Beam is first developing an approach known as ex vivo: cells are collected from a patient, modified in a laboratory and then readministered. Its BEAM-101 program, intended for sickle cell disease, involves editing blood stem cells to promote the production of fetal hemoglobin. Rather than directly repairing the mutation responsible for the disease, it therefore seeks to activate a mechanism that could compensate for its effects.
The second approach, known as in vivo, involves delivering the editing components directly into the body. BEAM-302 targets alpha-1 antitrypsin deficiency, a genetic disease that can cause lung and liver damage. This program aims to correct a mutation in liver cells through delivery using lipid nanoparticles.
These strategies pose distinct challenges. The first involves an individualized manufacturing chain and a demanding hospital treatment process. The second requires sufficiently efficient and selective delivery of the editor to the target tissue. In both cases, controlling unwanted modifications is a central concern.
What comes next?
For Beam Therapeutics, the next crucial step is to strengthen the clinical evidence: the magnitude of the benefit, the duration of the effect and long-term safety. The precision sought at the molecular level is not enough, on its own, to demonstrate a product’s therapeutic value.
The company must also lay the groundwork for a potential scale-up: reproducible manufacturing, quality control, care delivery and affordability of treatments. Its future will depend on its ability to turn a versatile editing platform into medicines with an established benefit-risk profile for each indication.